PHARMACY

Pradaxa added to CVS Caremark’s, Medco’s commercial preferred drug lists

BY Alaric DeArment

RIDGEFIELD, Conn. — A drug used to prevent stroke in patients with a form of atrial fibrillation has won preferred Tier 2 formulary status with pharmacy benefit managers Medco Health Solutions and CVS Caremark.

Boehringer Ingelheim Pharmaceuticals announced Monday that CVS Caremark and Medco had added Pradaxa (dabigatran etexilate mesylate) capsules to their commercial preferred drug lists, and Medco had added the drug to its Part D drug list.

“These formulary additions will offer nonvalvular atrial fibrillation patients increased access to Pradaxa, including its demonstrated ability to significantly reduce the risk of stroke over warfarin in this patient population,” Boehringer Ingelheim Pharmaceuticals VP cardiovascular and metabolic disorders marketing Wa’el Hashad said. “We look forward to a long relationship with CVS Caremark and Medco, and are committed to working with other pharmacy benefit managers, as well as offering our own programs to help make Pradaxa available to patients with nonvalvular atrial fibrillation.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Walgreens’ Pegus discusses evolving role of pharmacists at colloquium

BY Michael Johnsen

DEERFIELD, Ill. — The evolving role of the pharmacist and the growing impact of pharmacist interventions on clinical outcomes were discussed Tuesday by Walgreens chief medical officer Cheryl Pegus at the 11th annual Population Health and Care Coordination Colloquium in Philadelphia.

“Walgreens is confident that as the role of the pharmacist continues to grow, our diverse team of 70,000 healthcare service providers will be able to seize a unique opportunity to help patients become healthier by reaching them at both the community pharmacy and worksite,” Pegus said.

The session, titled “Impact and Value of Pharmacist Interventions in Different Settings,” examined the effect that pharmacists are having on patients through face-to-face interactions at both community pharmacies and employer worksite health clinics. “Today, innovative patient management models, such as accountable care organizations, medical homes and e-health offerings, are being proposed to help address the steep challenge of combating chronic diseases in the United States, but face significant resource challenges to delivering care,” Pegus said.

“Extensive data has shown that face-to-face interactions between patients and a trusted pharmacist can drive significant increases in adherence to medication, ultimately reducing costs to the system and resulting in better outcomes for patients,” she added. “As these new models are implemented, the opportunity to more broadly utilize pharmacists as providers both in the community and in the worksite will play a key role in how successful they can be.”

Pegus highlighted the broader range of services that are offered by today’s practicing pharmacist beyond simply dispensing medication, including drug monitoring and identifying drug interactions, education and patient counseling, chronic care management, immunizations, medication therapy management, formulary management and such public health initiatives as smoking cessation and diabetes education.

She also discussed how data has shown that pharmacists add value by providing easier access and higher levels of interaction and engagement with patients relative to other providers.

keyboard_arrow_downCOMMENTS

Leave a Reply

D.SPRAGUE says:
Aug-22-2011 03:36 pm

It is about time that someone has begun to take notice of the positive impact that good patient/pharmacist interaction has on patient self care behaviors and positive impacts on chronic disease care.

D.SPRAGUE says:
Aug-22-2011 03:36 pm

It is about time that someone has begun to take notice of the positive impact that good patient/pharmacist interaction has on patient self care behaviors and positive impacts on chronic disease care.

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Court rules in favor of Watson in generic Fentora patent suit

BY Alaric DeArment

MORRISTOWN, N.J. — A generic painkiller made by Watson Pharmaceuticals does not infringe on the patent covering the branded version, a U.S. District Court has ruled.

Watson said the U.S. District Court for the District of Delaware ruled that Watson’s generic version of Cephalon’s Fentora (fentanyl buccal tablets) does not infringe on two patents that were set to expire in March 2019, according to Food and Drug Administration records.

The FDA already had approved Watson’s version of the drug, though a third patent, U.S. Patent No. 6,264,981, remains in effect, preventing Watson’s launch of the drug.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?